Leveraging Science for Lifetime Medicine

From a one-man discovery to a passionate global drug development team working on the next generation of metabolic and inflammatory therapeutics

From Bench to Bedside

We leverage science to deliver effective, safe, and tolerable lifetime medicine for inflammatory diseases based on our deep understanding of drug research and development, breakthrough mechanisms of action, and global collaborations.

Pipeline
ARMOR Phase 3 Study
Sep. 9, 2026

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Read More
Aug. 19, 2026

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

Read More
Aug. 17, 2026

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Read More